A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Tilapertin (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms Study 299
- Sponsors Amgen
- 14 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Jun 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-004844-23).
- 23 Jun 2012 Additional trial locations (Singapore, Spain) identified as reported by EudraCT.